News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Pharvaris’ (Nasdaq: PHVS) $300 Million Follow-On OfferingDecember 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor and Placement Agent to Universal DX on its $70 Million Series B Financing and Strategic Collaboration with Quest DiagnosticsDecember 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)November 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor and Placement Agent for Q32 Bio’s Proposed Merger with Homology Medicines (Nasdaq: FIXX) and Concurrent $42 Million Private PlacementNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Exclusive Financial Advisor for Graphite Bio’s (Nasdaq: GRPH) Proposed Merger with LENZ TherapeuticsNovember 2023
News | NewsLeerink Partners Enhances Institutional Sales Team with Addition of Craig RoderNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Celldex Therapeutics’ (Nasdaq: CLDX) $200 Million Follow-on OfferingNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Alpine Immune Sciences’ (Nasdaq: ALPN) $150 Million Follow-On OfferingNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Lead-Left Bookrunner for Aura Biosciences’ (Nasdaq: AURA) $99 Million Follow-on OfferingNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Joint Bookrunner for Lexeo Therapeutics’ (Nasdaq: LXEO) $100 Million Initial Public OfferingNovember 2023
News | Deal AnnouncementLeerink Partners Serves as Global Coordinator and Joint Bookrunner for Nanobiotix’s (Nasdaq: NBTX) $30 Million Follow-on OfferingNovember 2023
